Journal article
Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial
- Abstract:
-
Importance
Developing effective vaccines against Ebola virus is a global priority.
Objective
To evaluate an adenovirus-type 26 vector vaccine encoding Ebola glycoprotein (Ad26.ZEBOV) and a modified vaccinia Ankara vector vaccine, encoding glycoproteins from Ebola virus, Sudan virus, Marburg virus and Tai Forest virus nucleoprotein (MVA-BN-Filo).
Design, Setting and Participants
Single-center, randomized, placebo-controlled, observer-blind, phase I t...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Crucell Holland B.V
More from this funder
Bibliographic Details
- Publisher:
- American Medical Association Publisher's website
- Journal:
- Journal of the American Medical Association Journal website
- Volume:
- 315
- Issue:
- 15
- Pages:
- 1610-1623
- Publication date:
- 2016-04-19
- Acceptance date:
- 2016-03-24
- DOI:
- ISSN:
-
0002-9955
Item Description
- Pubs id:
-
pubs:611644
- UUID:
-
uuid:88372212-f538-476c-808e-fef844ce1234
- Local pid:
- pubs:611644
- Source identifiers:
-
611644
- Deposit date:
- 2016-03-24
Terms of use
- Copyright holder:
- American Medical Association
- Copyright date:
- 2016
- Notes:
- © Copyright 2016 American Medical Association. All rights reserved.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record